Selected research
Industry Research
Lipid-lowering Agent Industry Research Report 2026
Market perspective
The global Lipid-lowering Agent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Lipid-lowering Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Lipid-lowering Agent is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Lipid-lowering Agent is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Lipid-lowering Agent include Abbott, Teva, SUN Pharma, Novartis, Merck, Pfizer, GlaxoSmithKline, Amgen and Abbvie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Lipid-lowering Agent market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lipid-lowering Agent Market by Company
Abbott
Teva
SUN Pharma
Novartis
Merck
Pfizer
GlaxoSmithKline
Amgen
Abbvie
AstraZeneca
Torrent Pharmaceuticals
JX Pharmaceuticals
HanAll BioPharma
Cerenis Therapeutics
Aurobindo Pharma
Lipid-lowering Agent Segment by Type
Acipimox
Fibrates
Niaci
Others
Lipid-lowering Agent Segment by Application
Hospitals
Clinics
Others
Lipid-lowering Agent Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lipid-lowering Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lipid-lowering Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lipid-lowering Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Lipid-lowering Agent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Lipid-lowering Agent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Lipid-lowering Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Acipimox
- Fibrates
- Niaci
- Others
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Abbott
- Teva
- SUN Pharma
- Novartis
- Merck
- Pfizer
- GlaxoSmithKline
- Amgen
- Abbvie
- AstraZeneca
- Torrent Pharmaceuticals
- JX Pharmaceuticals
- HanAll BioPharma
- Cerenis Therapeutics
- Aurobindo Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Lipid-lowering Agent Market Size (2021-2032)
- 2.2.2 Global Lipid-lowering Agent Sales (2021-2032)
- 2.2.3 Global Lipid-lowering Agent Market Average Price (2021-2032)
- 2.3 Lipid-lowering Agent by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Acipimox
- 2.3.3 Fibrates
- 2.3.4 Niaci
- 2.3.5 Others
- 2.4 Lipid-lowering Agent by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Lipid-lowering Agent Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Lipid-lowering Agent Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Lipid-lowering Agent Revenue of Manufacturers (2021-2026)
- 3.4 Global Lipid-lowering Agent Average Price by Manufacturers (2021-2026)
- 3.5 Global Lipid-lowering Agent Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Lipid-lowering Agent, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Lipid-lowering Agent, Product Type & Application
- 3.8 Global Manufacturers of Lipid-lowering Agent, Established Date
- 3.9 Global Lipid-lowering Agent Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Lipid-lowering Agent Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Lipid-lowering Agent Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 SUN Pharma
- 4.3.1 SUN Pharma Company Information
- 4.3.2 SUN Pharma Business Overview
- 4.3.3 SUN Pharma Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 SUN Pharma Lipid-lowering Agent Product Portfolio
- 4.3.5 SUN Pharma Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Lipid-lowering Agent Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Lipid-lowering Agent Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Lipid-lowering Agent Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 GlaxoSmithKline
- 4.7.1 GlaxoSmithKline Company Information
- 4.7.2 GlaxoSmithKline Business Overview
- 4.7.3 GlaxoSmithKline Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GlaxoSmithKline Lipid-lowering Agent Product Portfolio
- 4.7.5 GlaxoSmithKline Recent Developments
- 4.8 Amgen
- 4.8.1 Amgen Company Information
- 4.8.2 Amgen Business Overview
- 4.8.3 Amgen Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Amgen Lipid-lowering Agent Product Portfolio
- 4.8.5 Amgen Recent Developments
- 4.9 Abbvie
- 4.9.1 Abbvie Company Information
- 4.9.2 Abbvie Business Overview
- 4.9.3 Abbvie Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Abbvie Lipid-lowering Agent Product Portfolio
- 4.9.5 Abbvie Recent Developments
- 4.10 AstraZeneca
- 4.10.1 AstraZeneca Company Information
- 4.10.2 AstraZeneca Business Overview
- 4.10.3 AstraZeneca Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca Lipid-lowering Agent Product Portfolio
- 4.10.5 AstraZeneca Recent Developments
- 4.11 Torrent Pharmaceuticals
- 4.11.1 Torrent Pharmaceuticals Company Information
- 4.11.2 Torrent Pharmaceuticals Business Overview
- 4.11.3 Torrent Pharmaceuticals Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Torrent Pharmaceuticals Lipid-lowering Agent Product Portfolio
- 4.11.5 Torrent Pharmaceuticals Recent Developments
- 4.12 JX Pharmaceuticals
- 4.12.1 JX Pharmaceuticals Company Information
- 4.12.2 JX Pharmaceuticals Business Overview
- 4.12.3 JX Pharmaceuticals Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 JX Pharmaceuticals Lipid-lowering Agent Product Portfolio
- 4.12.5 JX Pharmaceuticals Recent Developments
- 4.13 HanAll BioPharma
- 4.13.1 HanAll BioPharma Company Information
- 4.13.2 HanAll BioPharma Business Overview
- 4.13.3 HanAll BioPharma Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 HanAll BioPharma Lipid-lowering Agent Product Portfolio
- 4.13.5 HanAll BioPharma Recent Developments
- 4.14 Cerenis Therapeutics
- 4.14.1 Cerenis Therapeutics Company Information
- 4.14.2 Cerenis Therapeutics Business Overview
- 4.14.3 Cerenis Therapeutics Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Cerenis Therapeutics Lipid-lowering Agent Product Portfolio
- 4.14.5 Cerenis Therapeutics Recent Developments
- 4.15 Aurobindo Pharma
- 4.15.1 Aurobindo Pharma Company Information
- 4.15.2 Aurobindo Pharma Business Overview
- 4.15.3 Aurobindo Pharma Lipid-lowering Agent Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Aurobindo Pharma Lipid-lowering Agent Product Portfolio
- 4.15.5 Aurobindo Pharma Recent Developments
5 Global Lipid-lowering Agent Market Scenario by Region
- 5.1 Global Lipid-lowering Agent Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Lipid-lowering Agent Sales by Region: 2021-2032
- 5.2.1 Global Lipid-lowering Agent Sales by Region: 2021-2026
- 5.2.2 Global Lipid-lowering Agent Sales by Region: 2027-2032
- 5.3 Global Lipid-lowering Agent Revenue by Region: 2021-2032
- 5.3.1 Global Lipid-lowering Agent Revenue by Region: 2021-2026
- 5.3.2 Global Lipid-lowering Agent Revenue by Region: 2027-2032
- 5.4 North America Lipid-lowering Agent Market Facts & Figures by Country
- 5.4.1 North America Lipid-lowering Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Lipid-lowering Agent Sales by Country (2021-2032)
- 5.4.3 North America Lipid-lowering Agent Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Lipid-lowering Agent Market Facts & Figures by Country
- 5.5.1 Europe Lipid-lowering Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Lipid-lowering Agent Sales by Country (2021-2032)
- 5.5.3 Europe Lipid-lowering Agent Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Lipid-lowering Agent Market Facts & Figures by Country
- 5.6.1 Asia Pacific Lipid-lowering Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Lipid-lowering Agent Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Lipid-lowering Agent Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Lipid-lowering Agent Market Facts & Figures by Country
- 5.7.1 South America Lipid-lowering Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Lipid-lowering Agent Sales by Country (2021-2032)
- 5.7.3 South America Lipid-lowering Agent Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Lipid-lowering Agent Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Lipid-lowering Agent Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Lipid-lowering Agent Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Lipid-lowering Agent Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Lipid-lowering Agent Sales by Type (2021-2032)
- 6.1.1 Global Lipid-lowering Agent Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Lipid-lowering Agent Sales Market Share by Type (2021-2032)
- 6.2 Global Lipid-lowering Agent Revenue by Type (2021-2032)
- 6.2.1 Global Lipid-lowering Agent Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Lipid-lowering Agent Revenue Market Share by Type (2021-2032)
- 6.3 Global Lipid-lowering Agent Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Lipid-lowering Agent Sales by Application (2021-2032)
- 7.1.1 Global Lipid-lowering Agent Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Lipid-lowering Agent Sales Market Share by Application (2021-2032)
- 7.2 Global Lipid-lowering Agent Revenue by Application (2021-2032)
- 7.2.1 Global Lipid-lowering Agent Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Lipid-lowering Agent Revenue Market Share by Application (2021-2032)
- 7.3 Global Lipid-lowering Agent Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Lipid-lowering Agent Value Chain Analysis
- 8.1.1 Lipid-lowering Agent Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Lipid-lowering Agent Production Mode & Process
- 8.2 Lipid-lowering Agent Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Lipid-lowering Agent Distributors
- 8.2.3 Lipid-lowering Agent Customers
9 Global Lipid-lowering Agent Analyzing Market Dynamics
- 9.1 Lipid-lowering Agent Industry Trends
- 9.2 Lipid-lowering Agent Industry Drivers
- 9.3 Lipid-lowering Agent Industry Opportunities and Challenges
- 9.4 Lipid-lowering Agent Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst